Based on solid research in mitochondrial myopathy by Professor Anu Wartiovaara, NAD was discovered to play a central role in the disease. NADMED technology translates this fundamental research on cellular metabolism into precision diagnostic tools for professional laboratories worldwide. The company's core innovation enables accurate measurement of NAD from blood, tissue, or cell samples. NADMED's CE-marked kits make metabolic health tracking accessible and cost-effective at scale, serving clinicians, researchers, and clinical trial teams across more than 40 countries. The company is trusted by institutions including HUS Laboratories, Cleveland Clinic, and Newcastle University.
Contact: Anu Suomalainen Wartiovaara, Professor, Board Chairperson & Co-Founder — anu.wartiovaara@helsinki.fi
